Fernando Telles | Founder & CEO
AuditLog.AI

Dr Fernando Telles is an Australian clinician-scientist focused on reproducibility and audit-trail integrity for clinical trials. He completed a Doctor of Medicine with Distinction (First Class Honours, top 5% Victoria) at the University of Melbourne and a Scholarly Selective at the University of Oxford's Radcliffe Department of Medicine under Prof. Paul Leeson, graduating with a final-year mark of 96%. He held an Honorary Research Contract with the University of Oxford (2016–2021), and the Baker Heart and Diabetes Institute (2017–2023) under Prof. Tom Marwick, where he was awarded the Baker's Quarterly Prize for Publication Excellence and 1st place at the CSANZ Annual Scientific Meeting in heart failure research. In 2025 he founded AuditLog.AI, supported by the Australian Government R&D Program. His current research addresses post-export clinical trial evidence integrity. Under his leadership, a single site proof-of-concept study was completed. In blinded, multi-operator, cross-platform audit verification, the study demonstrated that post-export clinical trial evidence can be verified deterministically using hash-based invariants, without reliance on the originating system or transfer of data custody. Across more than 230,000 evidence artefacts, verification achieved 100% sensitivity with zero false positives, and produced reproducible outcomes independent of operator and execution environment. The manuscript is under review by The Lancet Digital Health. Given the potential impact of the study findings for the long-term reliability of clinical data, Dr. Telles is currently coordinating a multi-site, international audit trial to externally confirm the findings. The pre-registered trial (https://doi.org/10.17605/OSF.IO/WP73B) is open for registrations to CROs and eligible research institutions, with Harvard Medical School (Boston Children’s Hospital) participation confirmed. ORCID: 0000-0003-2379-2875 | auditlog.ai